CSIMarket
 
Sangui Biotech International Inc  (SGBI)
Other Ticker:  
 
 
Price: $0.0015 $0.00 0.000%
Day's High: $0.0015 Week Perf: -48.28 %
Day's Low: $ 0.00 30 Day Perf: -87.6 %
Volume (M): 200 52 Wk High: $ 0.02
Volume (M$): $ 0 52 Wk Avg: $0.00
Open: $0.00 52 Wk Low: $0.00



 Market Capitalization (Millions $) 0
 Shares Outstanding (Millions) 210
 Employees -
 Revenues (TTM) (Millions $) 0
 Net Income (TTM) (Millions $) 0
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Sangui Biotech International Inc
Sangui Biotech International Inc is a biotechnology company that specializes in the development and production of innovative medical products. The company focuses on the field of oxygenation and blood plasma technology, aiming to provide safe and effective solutions for various medical applications. Sangui Biotech's primary product is a wound care product line called HemoStyp, which is designed to stop bleeding quickly and efficiently. The company also conducts research and development in other medical fields, such as cardiovascular diseases and regenerative medicine. Sangui Biotech International Inc is committed to advancing healthcare through its cutting-edge technologies and products.


   Company Address: Bleichenbrücke 9 Hamburg 20354
   Company Phone Number: 46093120   Stock Exchange / Ticker: SGBI
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Sangui Biotech International Inc

Headline: Sangui Biotech International Inc Struggles with Persistent Financial Stagnation, Reporting Revenues of Only $0.018697 Million for Fiscal Interval Ending March 31, 2023

Investors beware: Sangui Biotech International Inc is showing concerning signs of financial stagnation, with their fiscal interval ending March 31, 2023 resulting in zero gain per share. This represents a significant decrease from the previous year's earnings, which were also at zero, indicating a pattern of sustained lack of growth.
In addition, the slight increase in revenue of 4.138% from the previous year is hardly anything to write home about. While there was a sequential revenue surge of 75.939%, this increase is significantly less impressive when considering that the starting point was just $0.01 million.
The net shortfall of $-0.038 million, which is higher than the previous year's $-0.015 million, only adds to the growing concern of investors. This decrease in financial performance must not be ignored, as it is a clear sign of weak demand and competitiveness in the market.






 

Sangui Biotech International Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com